Melanoma Breslow Thickness and Staging
Stages cutaneous melanoma based on Breslow thickness, ulceration, and mitotic rate per AJCC 8th edition. Guides surgical margin and sentinel lymph node biopsy decisions.
Score interpretation
→ 5mm margin excision (in situ); 1cm margin for T1; sentinel node biopsy generally not recommended for T1a; dermatology follow-up 6-monthly x 2 years
→ 1cm margin excision; consider SLNB for T1b (ulcerated or mitoses); 1-2cm margin for T2; oncology referral; imaging for N staging
→ 2cm margin excision; SLNB recommended; full staging imaging (CT chest/abdomen/pelvis, MRI brain); oncology MDT; consider adjuvant immunotherapy (pembrolizumab/nivolumab) or targeted therapy if BRAF+
Interpretation bands for the Melanoma Breslow. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Omalizumab (Dermatology — Chronic Urticaria) · Anti-IgE Monoclonal Antibody
- Apremilast (Dermatology) · Phosphodiesterase-4 (PDE4) Inhibitor
- Chlorhexidine gluconate with isopropyl alcohol · Skin antiseptic
- Chlorhexidine with cetrimide · Skin antiseptic / wound cleanser
- Barrier creams and ointments · Topical skin protectant
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.